Acute Kidney Injury Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Acute Kidney Injury Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years.
• Acute Kidney Injury companies working in the treatment market are Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis Pharmaceuticals, and others, are developing therapies for the Acute Kidney Injury treatment
• Emerging Acute Kidney Injury therapies such as - REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.
• In March 2022, A Phase 2 randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to assess the efficacy and safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery was started by Guard Therapeutics AB.
• In October 2022, Guard Therapeutics declared that the FDA had approved the company's application for the investigational medicine RMC-035 (ROSgard), which was submitted as an Investigational New medicine (IND). The approval paves the way for the current worldwide and placebo-controlled Phase II research AKITA in cardiac surgery as well as the expansion of the clinical development programme for RMC-035 to the US
• In November 2022, Guard Therapeutics reported that the U.S. Food and Drug Administration (FDA) had given RMC-035(ROSgard) Fast Track designation for lowering the risk of irreversible kidney damage, the need for kidney replacement therapy, or death following open-chest cardiac surgery in patients who are more likely to suffer from acute kidney injury. With the objective of giving patients earlier access to these medications, the FDA's FastTrack programme is created to facilitate the development and speed up the review of novel pharmaceuticals intended to treat serious illnesses with a significant unmet medical need
• In March 2022, AM-Pharma will provide a presentation at the 27th International Conference on Advances in Critical Care Nephrology that will include a summary of the ongoing Phase III REVIVAL research
• In September 2021, Kyowa Kirin now has the exclusive rights to create and market ilofotase alfa in Japan according to an agreement between AM-Pharma and Kyowa Kirin.

Acute Kidney Injury Overview
An accumulation of nitrogenous products in the blood (azotemia), together with or without a decrease in urine production, are symptoms of acute kidney injury, which is characterised by a fast decline in renal function over a period of days to weeks. It frequently happens as a result of insufficient renal perfusion brought on by severe trauma, illness, or surgery, but it can also be brought on by an intrinsic renal disease that progresses quickly.

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:
• REVTx-300: Revelation Biosciences
• RGN-352: RegeneRx Biopharmaceuticals
• MTX652: MISSION Therapeutics
• UNI-494: Unicycive Therapeutics
• RBT-1: Rénibus Therapeutics
• SBI-101: Sentien Biotechnologies
• MIB-626: Metro International Biotech
• RMC-035: Guard Therapeutics AB
• TIN816: Novartis Pharmaceuticals

Route of Administration
Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Acute Kidney Injury Pipeline Therapeutics Assessment
• Acute Kidney Injury Assessment by Product Type
• Acute Kidney Injury By Stage and Product Type
• Acute Kidney Injury Assessment by Route of Administration
• Acute Kidney Injury By Stage and Route of Administration
• Acute Kidney Injury Assessment by Molecule Type
• Acute Kidney Injury by Stage and Molecule Type

DelveInsight's Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies at:
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute Kidney Injury Therapeutics Market include:
Key companies developing therapies for Acute Kidney Injury are - Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others.

Acute Kidney Injury Pipeline Analysis:
The Acute Kidney Injury pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies-
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Kidney Injury Pipeline Market Drivers
• Rising incidence of Acute Kidney injuries, the rising geriatric population are some of the important factors that are fueling the Acute Kidney Injury Market.

Acute Kidney Injury Pipeline Market Barriers
• However, side-effects associated with the treatment, lack of awareness and other factors are creating obstacles in the Acute Kidney Injury Market growth.

Scope of Acute Kidney Injury Pipeline Drug Insight
• Coverage: Global
• Key Acute Kidney Injury Companies: Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis Pharmaceuticals, and others
• Key Acute Kidney Injury Therapies: REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, and others
• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Acute Kidney Injury Report Introduction
2 Acute Kidney Injury Executive Summary
3 Acute Kidney Injury Overview
4 Acute Kidney Injury- Analytical Perspective In-depth Commercial Assessment
5 Acute Kidney Injury Pipeline Therapeutics
6 Acute Kidney Injury Late Stage Products (Phase II/III)
7 Acute Kidney Injury Mid Stage Products (Phase II)
8 Acute Kidney Injury Early Stage Products (Phase I)
9 Acute Kidney Injury Preclinical Stage Products
10 Acute Kidney Injury Therapeutics Assessment
11 Acute Kidney Injury Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Acute Kidney Injury Key Companies
14 Acute Kidney Injury Key Products
15 Acute Kidney Injury Unmet Needs
16 Acute Kidney Injury Market Drivers and Barriers
17 Acute Kidney Injury Future Perspectives and Conclusion
18 Acute Kidney Injury Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Acute Kidney Injury Market https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Kidney Injury-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Kidney Injury Epidemiology
https://www.delveinsight.com/report-store/acute-kidney-injury-aki-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Kidney Injury Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.